Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Analyzing ADB International Group (OTCMKTS:EQUR) & Neuronetics (NASDAQ:STIM)
01:59am, Monday, 02'nd Mar 2026
Neuronetics (NASDAQ: STIM - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both medical companies, but which is the better investment? We will compare the two compan
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update
01:40am, Thursday, 19'th Feb 2026
Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 8,588,113 shares, a growth of
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
12:20am, Wednesday, 11'th Feb 2026
Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 2025 revenue results.
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
04:34pm, Tuesday, 10'th Feb 2026
All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth o
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
08:30am, Thursday, 20'th Nov 2025
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
10:33am, Wednesday, 12'th Nov 2025
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States
Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript
12:26pm, Tuesday, 04'th Nov 2025
Neuronetics, Inc. ( STIM ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Keith Sullivan - President, CEO & Director Steven Pfanstiel - Executive VP, Treasurer & CFO Conferenc
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates
09:41am, Tuesday, 04'th Nov 2025
Neuronetics (STIM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.29 per share a year ago.
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
07:05am, Tuesday, 04'th Nov 2025
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25%
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 31'st Oct 2025
MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics New collaboration provides service
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 21'st Oct 2025
MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
08:32am, Wednesday, 17'th Sep 2025
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:45pm, Wednesday, 06'th Aug 2025
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript
12:53pm, Tuesday, 05'th Aug 2025
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Keith J. Sullivan - President, CEO & Director Steven E.
